Investee Company News

March 13, 2018 Melinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results March 8, 2018 Melinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application for Delafloxacin in Europe March 2, 2018 Melinta Therapeutics to Present at The Cowen and Company 38th Annual Health Care Conference February 28, 2018 Poseida Therapeutics Appoints Mark Gergen as Chief Business Officer and Chief Financial Officer February 28, 2018 Melinta Therapeutics To Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018 February 28, 2018 Melinta Therapeutics Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE™ in Patients with cUTI February 21, 2018 Dr. Eugene Sun Appointed to Novan Board of Directors February 20, 2018 Melinta Therapeutics’ Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for Delafloxacin in Argentina February 14, 2018 Poseida Therapeutics Presents Stem Cell Memory CAR-T Therapy for Prostate Cancer at 2018 Keystone Symposia on Emerging Cellular Therapies February 13, 2018 Novan to Present Integrated Data from Phase 3 Trials with SB204 for Treatment of Acne February 8, 2018 Immunocore Announces Leadership Change February 8, 2018 Novoclem announces CEO Anne Whitaker to present at the BIO CEO & Investor Annual Conference on Monday February 12th, 2018 February 5, 2018 Poseida Therapeutics Appoints Martin Giedlin, Ph.D., as Vice President, Technical Operations January 29, 2018 Melinta Therapeutics Launches Antibiotic Baxdela™ (delafloxacin) in the United States January 25, 2018 Novan Announces First Patient Dosed in Phase 2 Molluscum Contagiosum Trial with SB206 January 18, 2018 Melinta Therapeutics Announces Initiation of Program for Radezolid in Patients with Bacterial Vaginosis January 11, 2018 Xenex LightStrike Germ-Zapping Robots Helping Stanford Health Care – ValleyCare Destroy Germs and Bacteria January 11, 2018 Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference January 8, 2018 Melinta Therapeutics Completes Acquisition of The Medicines Company’s Infectious Disease Portfolio January 5, 2018 Novan Announces Pricing of $38.0 Million Offering of Common Stock and Warrants January 4, 2018 Novoclem announces CEO Anne Whitaker to present at the Biotech Showcase™ Annual Conference on Wednesday, January 10, 2018 January 4, 2018 Novan Announces Proposed Public Offering of Common Stock and Warrants January 4, 2018 Immunocore Strengthens its Board with Appointments of Laura Wade-Gery and Kristine Peterson as Non-Executive Directors January 3, 2018 Novoclem announces issuance of patent covering a core technology underlying its Cystic Fibrosis therapeutic development program January 3, 2018 NovaQuest Capital Management to Acquire Viamet Pharmaceuticals and the VT-1161 Antifungal Program December 19, 2017 Ochsner Medical Center Reports 49% Decrease in Infection Rates After Germ-Fighting Robots Deployed to Disinfect Patient Rooms December 18, 2017 Poseida Therapeutics Announces First Patient Treated in Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Therapy in Patients with Multiple Myeloma December 11, 2017 Immunocore’s IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma December 11, 2017 Multiple Programs Featuring Poseida Therapeutics’ Advanced CAR-T Therapies Presented at American Society of Hematology 2017 Annual Meeting December 5, 2017 Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101 at the American Association for Cancer Research Prostate Cancer Meeting